Search PubMed⌕ Search

Biomedical subjects

W H Daughaday

Publications and source records attributed to W H Daughaday.

At least 55 records · Page 3Linked to original sources
PubMed1987

Effects of insulin-like growth factor I (IGF-I) on growth hormone-releasing factor (GRF) and thyrotropin-releasing hormone (TRH) stimulation of growth hormone (GH) secretion in the domestic fowl (Gallus domesticus).

Recent studies in mammalian species indicate that IGF-I may act as a negative feedback inhibitor of GH release through alteration of pituitary secretion or sensitivity to hypothalamic regulatory factors. Although avian GH secretion appears to be regulated by the differential release of hypothalamic inhibitory (somatostatin) and stimulatory (GRF and TRH) factors, feedback effects of IGF-I on in vivo GH release in birds have not been investigated. To study the effects of elevated IGF-I concentration on GRF- and TRH-stimulated GH secretion, 4-week-old chickens received an intravenous injection of recombinant human IGF-I either 15 min prior to (6 micrograms, study 1), or simultaneous with (10 micrograms, study 2). GRF (hGRF44NH2, 5 micrograms/kg) or TRH (0.5 microgram/kg) administration. Radioimmunoassay analysis of plasma collected prior to and following peptide treatment indicated that circulating IGF-I concentrations were elevated 83.9, 60.6, 77.9, and 88.8% at the time of TRH and GRF administration in studies 1 and 2, respectively. Peak GH concentrations (mean of +5- and +15-min samples) subsequent to TRH injection were significantly (P less than 0.01) depressed 45.1 and 48.2% in IGF-I-treated as compared with control chicks in the first and second studies, respectively. GRF-stimulated GH secretion was significantly (P less than 0.01) decreased by IGF-I administration in study 2 (41.3%) but not in study 1. An estimated half-life for IGF-I in the chicken is less than 15 min based on the disappearance rate of the elevation produced by exogenous IGF-I injections. Thus, IGF-I exerts a negative feedback effect on pituitary hormone secretion in avian as well as mammalian species.

Animals↗
PubMed1987

Evidence for the role of insulin-like growth factor II (IGF-II) in the control of food intake.

Highly purified insulin-like growth factors I and II and insulin (100 ng peptide/animal) were injected intracerebroventricularly in rats and the effect on 24 hour food consumption examined. IGF-II injections resulted in a 21% decrease in food intake and 4% body weight loss over the 24 hour period following peptide administration whereas IGF-I and insulin had no effect on either parameter. Increasing the amount of IGF-II injected also increased these responses with depressions of 22, 33 and 44% occurring in rats given 33, 100 and 300 ng IGF-II respectively. In addition, tissue concentrations of IGF-II were detected and found to be differentially distributed, via radioimmunoassay, in specific regions of the brain implicated in the regulation of food intake. IGF-I was not found in these same tissue punches despite radioimmunoassay sensitivity of 6 pg.

Animals↗
PubMed1987

Absence of serum growth hormone binding protein in patients with growth hormone receptor deficiency (Laron dwarfism).

It has recently been recognized that human serum contains a protein that specifically binds human growth hormone (hGH). This protein has the same restricted specificity for hGH as the membrane-bound GH receptor. To determine whether the GH-binding protein is a derivative of, or otherwise related to, the GH receptor, we have examined the serum of three patients with Laron-type dwarfism, a condition in which GH refractoriness has been attributed to a defect in the GH receptor. The binding of 125I-labeled hGH incubated with serum has been measured after gel filtration of the serum through an Ultrogel AcA 44 minicolumn. Nonspecific binding was determined when 125I-hGH was incubated with serum in the presence of an excess of GH. Results are expressed as percent of specifically bound 125I-hGH and as specific binding relative to that of a reference serum after correction is made for endogenous GH. The mean +/- SEM of specific binding of sera from eight normal adults (26-46 years of age) was 21.6 +/- 0.45%, and the relative specific binding was 101.1 +/- 8.6%. Sera from 11 normal children had lower specific binding of 12.5 +/- 1.95% and relative specific binding of 56.6 +/- 9.1%. Sera from three children with Laron-type dwarfism lacked any demonstrable GH binding, whereas sera from 10 other children with other types of nonpituitary short stature had normal relative specific binding. We suggest that the serum GH-binding protein is a soluble derivative of the GH receptor. Measurement of the serum GH-binding protein may permit recognition of other abnormalities of the GH receptor.

Adolescent↗
PubMed1987

Stimulation of supranormal growth in prepubertal, adult plateaued, and hypophysectomized female rats by large doses of rat growth hormone: physiological effects and adverse consequences.

A supranormal rate of growth in intact, prepubertal, 26-day-old female rats was evoked by administration of large doses of highly purified rat GH (rGH). In response to daily doses of 1 and 5 mg/rat (13.6 mg/kg BW and 68 mg/kg BW), sc, for 20 days, body weight (BW) gain increased 51% and 73%, and skeletal growth increased 27% and 40%, respectively. Serum rGH in treated rats rose as much as 69-fold greater than that of controls. Feed efficiency, the ratio of weight gained to feed consumed, increased from 19.8% to 32.0%. This rGH treatment depleted pituitary GH content as much as 58% and caused hepatomegaly. These effects, as well as the accelerated growth rate, reverted to normal after cessation of rGH treatment. Onset of puberty in rGH-treated rats was delayed an average of 2.7 days. A similar stimulatory effect on BW gain, but not skeletal growth, as well as depletion of pituitary GH content, and hepatomegaly, was elicited by rGH treatment in adult, plateaued female rats. These effects in plateaued rats reverted to normal after cessation of GH treatment, and 50% of the body weight gain was rapidly lost. The largest dose of rGH used, 5 mg/day, was apparently toxic, resulting in a 20% higher mortality rate in treated prepubertal and plateaued female rats. Antibody formation was not the cause of the toxicity, since antibodies against rGH were undetectable at the lowest dilutions of serum tested. Serum rat insulin-like growth factor I (RIA), 3.5 U/ml in untreated intact prepubertal rats, increased to 4.7 and 5.0 U/ml, respectively, after 20 days of rGH treatment. In hypophysectomized rats, serum rat insulin-like growth factor I (RIA), undetectable in controls, was increased to 1.63 U/ml after 14 days treatment with 1 mg rGH/day. This study demonstrates that greater than normal growth can be stimulated in normal female rats by administration of large doses of homologous GH, but at the risk of serious adverse effects. Possible implications for the administration of GH to non-GH-deficient children, to promote taller stature, are clear.

Animals↗
PubMed1987

Measurement of insulin-like growth factor I (IGF-I) responsiveness of fibroblasts of children with short stature: identification of a patient with IGF-I resistance.

Somatomedins are important mediators of GH action on skeletal tissues. A possible cause of growth failure, therefore, is impaired somatomedin (Sm) responsiveness of the target tissues. To investigate Sm responsiveness, we studied fibroblasts from 11 normal-statured individuals and 9 patients with short stature. Five of the short patients had normal serum GH and normal or increased Sm levels and, therefore, are considered possibly to be Sm resistant. The other short patients include 2 with Laron-type dwarfism and 2 with GH resistance of undefined type. As a measure of Sm responsiveness, we determined the ability of insulin-like growth factor I (IGF-I; Sm-C) to stimulate uptake of [3H]alpha-aminoisobutyric acid by fibroblasts. The mean ED50 of the 11 normal fibroblast cell lines was 3.2 +/- 0.9 (+/- SD) ng/ml. Fibroblasts from 8 of the 9 short-statured patients had ED50 values within the normal range. This included 2 fibroblast lines isolated from children with Laron-type dwarfism. Fibroblasts from 1 patient, however, were significantly less sensitive to IGF-I in 9 separate assays, with an ED50 of 10.7 +/- 1.8 ng/ml. Fibroblasts from the mother of the patient had an ED50 of 5.0 +/- 1.4 ng/ml, and fibroblasts from the father had an ED50 of 4.3 +/- 0.7 ng/ml, both above the normal mean. Measurements of [125I]IGF-I binding by suspended fibroblasts from this patient and her parents failed to demonstrate significant abnormalities in either the number of binding sites or the affinity of binding. We conclude that the ability of IGF-I to stimulate [3H]alpha-aminoisobutyric acid uptake by human fibroblasts provides a useful method of identifying short children with Sm resistance. Of five patients with clinical evidence of possible Sm resistance, fibroblasts from one consistently were hyporesponsive to IGF-I. Cells from two patients with Laron-type dwarfism were normally responsive to IGF-I.

Aminoisobutyric Acids↗
PubMed1987

Characterization of serum growth hormone (GH) and insulin-like growth factor I in active acromegaly with minimal elevation of serum GH.

In most patients with acromegaly basal serum GH concentrations are elevated and remain above 5 micrograms/L after oral glucose administration. In some patients, however, serum insulin-like growth factor I (IGF-I) concentrations are elevated with only minimal elevations of serum GH. We studied the serum GH and IGF-I of two such patients to determine whether these peptide hormones are normal in this clinical situation. The serum GH of these patients was found to bind normally to receptors of the IM-9 lymphocyte. The elution pattern of IGF-I extracted from the patients' serum was similar to that of (Thr59) human IGF-I after passage through a Bio-Rad P-60 column in 0.5 M acetic acid. The IGF-I was further characterized by isoelectric focusing and C18 reverse phase high pressure liquid chromatography (HPLC). The isoelectric points of the IGF-I components were similar to those of IGF-I in normal serum. The IGF-I in one patient had two components by HPLC, while that of the other patient had only one major component. The IGF-I components isolated by HPLC were normally active in stimulating [3H] alpha-aminoisobutyric acid uptake by normal human fibroblasts. The elevated serum IGF-I concentrations of these two patients were GH dependent. Transsphenoidal adenomectomy in one patient resulted in a decline in serum IGF-I to a high normal concentration. Lowering the serum GH to subnormal concentrations by the administration of the somatostatin analog SMS 201-995 (Sandoz) restored normal IGF-I concentrations in the second patient. We conclude that the GH and IGF-I of these two patients cannot account for their apparent enhanced GH responsiveness.

Acromegaly↗
PubMed1987

The ontogeny of serum GH binding protein in man: a possible indicator of hepatic GH receptor development.

Experiments in rabbits suggest that a serum GH binding protein (GH-BP) probably is derived largely from hepatic membrane bound GH receptors. Human serum contains a specific GH binding protein which can be easily measured by incubation with [125I] hGH and separation of [125I] hGH-BP complexes from free [125I] hGH by gel filtration through an Ultrogel AcA 44 minicolumn. In each assay GH-BP activity of a reference (normal young adult) serum is similarly run and the results are expressed as a percentage of the activity of the unknown serum divided by the GH-BP activity of the reference serum after correction for the expected inhibition of GH binding resulting from the GH content of the unknown serum. The mean relative specific GH binding protein (RSGH-BP) of cord serum from 11 premature infants was only 3.2 +/- 1.4% (SE) and of cord serum from 17 full term infants was 14.9 +/- 2.5%. During the first two decades of life there was a progressive rise of RSGH-BP with considerable individual variation. The mean serum RSGH-BP of 13 such subjects was 54.5 +/- 6.2%. More uniform RSGH-BP results were obtained in serum from 15 young adults, 91.7 +/- 7.4%. Lower RSGH-BP 77.2 +/- 5.4% was found in serum from 12 healthy older adults (age 60 to 70 years). The low levels of RSGH-BP in fetal serum are consistent with the reported low concentrations of GH receptors in sheep and rat fetal liver membranes. We suggest the measurement of GH-BP activity provides a simple, noninvasive measure of the ontogeny of GH receptors of human beings.

Adolescent↗
PubMed1987

Serum somatomedin binding proteins: physiologic significance and interference in radioligand assay.

Mammalian sera contain binding proteins that specifically complex with somatomedins (insulin-like growth factor I and II) so that there are no detectable free somatomedins. There is immunologic evidence of two distinct types of serum binding proteins. The major binding protein complex (150,000 Mr) is growth hormone dependent. Binding proteins protect somatomedins from proteolytic degradation, retard plasma clearance, and decrease the availability to tissue receptors. The presence of serum binding proteins interferes with radioimmunoassays and radioreceptor assays for somatomedins. Proposed strategies to neutralize the interference from binding proteins without their elimination do not achieve this goal. Extraction of somatomedins by acid ethanol, hydrophobic absorption on C18 silicates (SepPak), and acid gel filtration are effective with human serum, but only acid gel filtration is satisfactory with rat serum. Failure to eliminate binding proteins from assays can lead to serious artifacts in conditions where abnormalities of binding proteins exist.

Acromegaly↗
PubMed1987

Specific immunoradiometric assay of insulin-like growth factor I with use of monoclonal antibodies.

We identified two monoclonal antibodies that bind spatially distinct epitopes on insulin-like growth factor I (IGF-I). Using these two antibodies, we developed a simultaneous, two-site immunoradiometric assay (IRMA) specific for IGF-I. This IRMA has no detectable cross reactivity with insulin, proinsulin, prolactin, or somatotropin, and less than 2% crossreactivity with IGF-II. The assay response varies linearly with IGF-I concentrations of 0-800 micrograms/L in serum; the detection limit is about 10 micrograms/L. A comparison of 26 IGF-I serum values from the IRMA and from a previously reported IGF-I specific RIA gave a correlation coefficient of 0.96 with no substantial bias (slope = 1.10). IGF-I values for serum, as an aid in assessing growth abnormalities, are easily (only three pipetting steps) obtained in less than 4 h.

Animals↗
PubMed1986

Insulin-like growth factors I and II in maternal and fetal guinea pig serum.

The role of insulin-like growth factors (IGFs) in fetal development has been the subject of much speculation. We undertook studies of maternal and fetal IGF I and II in the guinea pig because the long gestation period and greater size of the fetuses permitted blood sampling over a longer period of gestation and maturation than is possible in the rat. Acid gel filtrates of fetal and maternal serum were prepared, and the IGF I was measured by RIA; IGF II was measured by rat placental membrane radioreceptor assay. Fetal IGF I levels were lower than maternal levels from the 33rd day of estimated gestation to term. Fetal IGF II levels from the 33rd day to the 49th day of gestation were not significantly different from those of maternal serum [1597 +/- 377 (SE) ng/ml vs. 1295 +/- 224] ng/ml. Very high levels of IGF II, in excess of 5000 ng/ml, were observed in fetuses at 50, 55, and 60 days of gestation. Thereafter, fetal IGF II levels fell markedly before term. Fetal and maternal IGFs after 49, 50, 60, and 65 days of pregnancy were compared by isoelectric focusing. The guinea pig normally has two major basic peaks of IGF I, which were present both in maternal and fetal serum. Most maternal and fetal guinea pig sera contained only a single, slightly acidic peak of IGF II. No evidence of a unique fetal IGF was detected by our methods. The very high levels of IGF II reached in fetal guinea pig sera suggest that it may have a role in fetal development.

Animals↗
PubMed1985

Insulin-like growth factors I and II of nonmammalian sera.

We have compared the insulin-like growth factors (IGFs) of a number of mammalian and nonmammalian vertebrate sera. Sera were subjected to acid gel filtration through G-75 Sephadex and separate binding protein and free IGF fractions were pooled. The IGF pools were subjected to flatbed isoelectric focusing and the concentration of IGF I in the fractions was detected with an immunoassay using 125I-hIGF I and the somatomedin C antibody of Underwood and Van Wyk. IGF II in the fractions was detected with either the 125I-IGF rat placental membrane RRA or the 125I-IGF II serum binding protein assay. One or more basic peaks of IGF I immunoactivity were detected in all the mammalian sera studied (human, guinea pig, rat, bovine, kangaroo, and opossum) and all the nonmammalian species studied (chicken, turtle, toad, and trout). Neutral and slightly acidic peaks of IGF II receptor reactivity were observed in human, cow, and guinea pig serum. No distinct peaks of IGF II were observed in adult rat, opossum, or kangaroo serum. Distinct peaks of IGF II activity in the neutral to slightly acidic range were clearly recognized in chicken and turtle serum, no such peaks were recognized in toad and trout serum. All mammalian sera studied contained acid stable, binding proteins with high affinity, saturable binding of 125I-IGF II. None of the nonmammalian sera studied contained demonstrable specific 125I-IGF II binding. These observations document the presence of separate IGF I and IGF II peptides in chickens and turtles but only IGF I in amphibians and fish. These observations indicate that the gene duplication giving rise to two separate IGFs arose before reptilian evolution. The acquisition of a specific IGF binding protein is limited to mammals.

Animals↗